The scientific community have highlighted the potential of Scancell Holdings Plc’s (LON:SCLP) in-development cancer vaccines.
Scancell’s technology – which promises a completely new class of immuno-oncology therapeutics – has been peer reviewed in a scientific journal.
The report, in the Autophagy journal, discussed Scancell's pre-clinical supporting the innovation and potential of the company’s Moditope platform.
Scancell’s chief scientific officer Professor Lindy Durrant is lead author of the review, which discusses the concept that citrullinated peptides produced during autophagy offer attractive vaccine targets for cancer therapy.
Data described in the review - which had been separately published in another peer-reviewed journal – showed that a single immunization with Moditope resulted in long-term survival in up to 90% of mice.
“Moditope has a unique mechanism of action that overcomes the immune suppression induced by tumour cells, allowing T cells to seek out and kill tumours that would otherwise be hidden from the immune system,” Durrant said in a statement.
“We believe this platform has the potential to develop a new class of immuno-oncology therapeutics and look forward to progressing our first vaccine into the clinic as soon as possible."
It is expected that the first clinical trial coming from the platform will target patients with triple negative breast cancer, ovarian cancer and osteosarcoma.